Search

Your search keyword '"Carraro M"' showing total 583 results
Start Over Author "Carraro M"
583 results on '"Carraro M"'

1. A nanoporous surface is essential for glomerular podocyte differentiation in three-dimensional culture

Author

Zennaro C, Rastaldi MP, Bakeine GJ, Delfino R, Tonon F, Farra R, Grassi G, Artero M, Tormen M, and Carraro M

Subjects
podocytes, neurons, nanotechnology, basement membrane, differentiation, adhesion, Medicine (General), R5-920
Abstract

Cristina Zennaro,1 Maria Pia Rastaldi,2 Gerald James Bakeine,3 Riccarda Delfino,1 Federica Tonon,1 Rossella Farra,4 Gabriele Grassi,1,5 Mary Artero,6 Massimo Tormen,7 Michele Carraro1 1Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, 2Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, 3Department of Radiology, San Martino University Hospital, University of Genoa, Genoa, 4Department of Engineering and Architecture, University of Trieste, 5Department of Life Sciences, Cattinara University Hospital, University of Trieste, 6Azienda Sanitaria Universitaria Integrata di Trieste, Trieste, 7IOM-CNR Area Science Park, Trieste, Italy Abstract: Although it is well recognized that cell–matrix interactions are based on both molecular and geometrical characteristics, the relationship between specific cell types and the three-dimensional morphology of the surface to which they are attached is poorly understood. This is particularly true for glomerular podocytes – the gatekeepers of glomerular filtration – which completely enwrap the glomerular basement membrane with their primary and secondary ramifications. Nanotechnologies produce biocompatible materials which offer the possibility to build substrates which differ only by topology in order to mimic the spatial organization of diverse basement membranes. With this in mind, we produced and utilized rough and porous surfaces obtained from silicon to analyze the behavior of two diverse ramified cells: glomerular podocytes and a neuronal cell line used as a control. Proper differentiation and development of ramifications of both cell types was largely influenced by topographical characteristics. Confirming previous data, the neuronal cell line acquired features of maturation on rough nanosurfaces. In contrast, podocytes developed and matured preferentially on nanoporous surfaces provided with grooves, as shown by the organization of the actin cytoskeleton stress fibers and the proper development of vinculin-positive focal adhesions. On the basis of these findings, we suggest that in vitro studies regarding podocyte attachment to the glomerular basement membrane should take into account the geometrical properties of the surface on which the tests are conducted because physiological cellular activity depends on the three-dimensional microenvironment. Keywords: podocytes, neurons, nanotechnology, basement membrane, differentiation, adhesion

Published
2016

3. Optimizing the ITER NBI ion source by dedicated RF driver test stand

Author

Mario, I., primary, Pimazzoni, A., additional, Sartori, E., additional, Pouradier-Duteil, B., additional, Sheperd, A., additional, Denizeau, S., additional, Casagrande, R., additional, Agnello, R., additional, Agostini, M., additional, Aprile, D., additional, Barbato, P., additional, Baseggio, L., additional, Battistella, M., additional, Berton, G., additional, Boldrin, M., additional, Brombin, M., additional, Candeloro, V., additional, Carraro, M., additional, Cinetto, P., additional, Dal Bello, S., additional, Delogu, R., additional, Fadone, M., additional, Fellin, F., additional, Fincato, M., additional, Franchin, L., additional, Friso, D., additional, Grando, L., additional, La Rosa, A., additional, Laterza, B., additional, López-Bruna, D., additional, Magagna, M., additional, Maniero, M., additional, Marconato, N., additional, Pasqualotto, R., additional, Passalacqua, G., additional, Pavei, M., additional, Poggi, C., additional, Ravarotto, D., additional, Rigoni-Garola, A., additional, Romanato, L., additional, Rossetto, F., additional, Segalini, B., additional, Sonato, P., additional, Taliercio, C., additional, Toigo, V., additional, Tollin, M., additional, Ugoletti, M., additional, Vignando, M., additional, Zagórski, R., additional, Zaniol, B., additional, Zaupa, M., additional, Zella, D., additional, Zerbetto, E., additional, Zucchetti, S., additional, Zuin, E., additional, and Serianni, G., additional

Published
2024
Full Text
View/download PDF

4. Direct determination of chronic myeloid leukemia prevalence in Lombardy—Italy: Global implications.

Author

Polverelli, N., Anghilieri, M., Elena, C., Intermesoli, T., Pungolino, E., D'Adda, M., Iurlo, A., Maffioli, M., Lunghi, F., Bertolli, V., Orofino, N., Sissa, C., Fiamenghi, C., Gardellini, A., Ubezio, M., Carraro, M. C., Corradini, P., Giglio, F., Pasquini, M. C., and Palazzolo, R.

Subjects
CHRONIC myeloid leukemia, PROTEIN-tyrosine kinase inhibitors, RECORD collecting, IMATINIB, HEMATOLOGY
Abstract

Lombardy represents the largest region of Italy by population, with almost 10 million residents, a dimension similar to a medium size country like Sweden or Belgium. The CML subcommittee of the Lombardy Hematology Network (REL‐CML) conducted a study at the beginning of 2023. Prevalence was calculated by direct input from the 21 centers participating in REL‐CML. Tyrosine Kinase Inhibitors (TKI) prescription records collected from the ARIA regional registry were used to estimate the number of CML patients followed in smaller centers not participating in REL‐CML. A total of 2285 patients were registered, representing a prevalence of 0.23 ‰. These data were compared to a similar census conducted in 2005, at the beginning of the TKI era, where a prevalence of 0.029‰ was calculated. This indicates that an almost 10 times increase took place during this period of time. Imatinib represents the most frequently prescribed first‐line TKI; its use in 2022 still represented 75% of total first line prescriptions. An increased concentration of the care of CML patients in specialized REL centers with a decreased dispersion of patients in small centers was also evident over this 18 year period of time. Nineteen % of patients discontinued treatment, highlighting persisting logistical and biological challenges; one some recommendations on CML management are included to this aim. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Impaired flickering of the permeability transition pore causes SPG7 spastic paraplegia

Author

Sambri, I, Massa, F, Gullo, F, Meneghini, S, Cassina, L, Carraro, M, Dina, G, Quattrini, A, Patanella, L, Carissimo, A, Iuliano, A, Santorelli, F, Codazzi, F, Grohovaz, F, Bernardi, P, Becchetti, A, Casari, G, Sambri I., Massa F., Gullo F., Meneghini S., Cassina L., Carraro M., Dina G., Quattrini A., Patanella L., Carissimo A., Iuliano A., Santorelli F., Codazzi F., Grohovaz F., Bernardi P., Becchetti A., Casari G., Sambri, I, Massa, F, Gullo, F, Meneghini, S, Cassina, L, Carraro, M, Dina, G, Quattrini, A, Patanella, L, Carissimo, A, Iuliano, A, Santorelli, F, Codazzi, F, Grohovaz, F, Bernardi, P, Becchetti, A, Casari, G, Sambri I., Massa F., Gullo F., Meneghini S., Cassina L., Carraro M., Dina G., Quattrini A., Patanella L., Carissimo A., Iuliano A., Santorelli F., Codazzi F., Grohovaz F., Bernardi P., Becchetti A., and Casari G.

Abstract

Background: Mutations of the mitochondrial protein paraplegin cause hereditary spastic paraplegia type 7 (SPG7), a so-far untreatable degenerative disease of the upper motoneuron with still undefined pathomechanism. The intermittent mitochondrial permeability transition pore (mPTP) opening, called flickering, is an essential process that operates to maintain mitochondrial homeostasis by reducing intra-matrix Ca2+ and reactive oxygen species (ROS) concentration, and is critical for efficient synaptic function. Methods: We use a fluorescence-based approach to measure mPTP flickering in living cells and biochemical and molecular biology techniques to dissect the pathogenic mechanism of SPG7. In the SPG7 animal model we evaluate the potential improvement of the motor defect, neuroinflammation and neurodegeneration by means of an mPTP inducer, the benzodiazepine Bz-423. Findings: We demonstrate that paraplegin is required for efficient transient opening of the mPTP, that is impaired in both SPG7 patients-derived fibroblasts and primary neurons from Spg7−/− mice. We show that dysregulation of mPTP opening at the pre-synaptic terminal impairs neurotransmitter release leading to ineffective synaptic transmission. Lack of paraplegin impairs mPTP flickering by a mechanism involving increased expression and activity of sirtuin3, which promotes deacetylation of cyclophilin D, thus hampering mPTP opening. Pharmacological treatment with Bz-423, which bypasses the activity of CypD, normalizes synaptic transmission and rescues the motor impairment of the SPG7 mouse model. Interpretation: mPTP targeting opens a new avenue for the potential therapy of this form of spastic paraplegia. Funding: Telethon Foundation grant (TGMGCSBX16TT); Dept. of Defense, US Army, grant W81XWH-18–1–0001

Published
2020

18. Deferasirox in the management of iron-overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (IRON-M study)

Author

Elli, E, Iurlo, A, Aroldi, A, Caramella, M, Malato, S, Casartelli, E, Maffioli, M, Gardellini, A, Carraro, M, D'Adda, M, Polverelli, N, Rossi, M, Orofino, N, Carrer, A, Gambacorti-Passerini, C, Antolini, L, Passamonti, F, Elli E. M., Iurlo A., Aroldi A., Caramella M., Malato S., Casartelli E., Maffioli M., Gardellini A., Carraro M. C., D'Adda M., Polverelli N., Rossi M., Orofino N., Carrer A., Gambacorti-Passerini C., Antolini L., Passamonti F., Elli, E, Iurlo, A, Aroldi, A, Caramella, M, Malato, S, Casartelli, E, Maffioli, M, Gardellini, A, Carraro, M, D'Adda, M, Polverelli, N, Rossi, M, Orofino, N, Carrer, A, Gambacorti-Passerini, C, Antolini, L, Passamonti, F, Elli E. M., Iurlo A., Aroldi A., Caramella M., Malato S., Casartelli E., Maffioli M., Gardellini A., Carraro M. C., D'Adda M., Polverelli N., Rossi M., Orofino N., Carrer A., Gambacorti-Passerini C., Antolini L., and Passamonti F.

Published
2019

20. Final and Manufacturing Design of MITICA Control Room

Author

Carraro M.

Subjects
MITICA, Neutral Beam Test Facility, ComputingMethodologies_DOCUMENTANDTEXTPROCESSING, NBTF, MITICA Control Rooms
Abstract

This document reports the final and manufacturing design of the MITICA Control Room.

Published
2021

21. Validare le pratiche collaborative per l’economia circolare urbana: il punto di vista del design

Author

De Salvo, V., Carraro, M., Bianchini, M., Maffei, S., De Salvo, Veronica, Carraro, Michelangelo, Bianchini, Massimo, and Maffei, Stefano

Subjects
Urban circular economy, Validation, Theory of change, Coproduction, Settore ICAR/13 - Disegno Industriale
Abstract

The article presents the results of the research activity carried out within the framework of the European project H2020 REFLOW, which aims to build an integrated approach for the development of innovative participatory practices dedicated to urban circular metabolisms. As a result of the survey conducted on the application of collaborative models for the urban circular economy, it emerged that there is no shared operational strategy that can be adopted for the circular development of complex systems, such as cities. Based on this premise, this paper offers a new perspective on how to build and validate a transitional pathway for the development of circular cities through the adoption of a design-oriented approach that orchestrates different resources and capacities.

Published
2021

22. Nilotinib-induced bone marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-Chronic Myeloid Leukemia: Final report of the PhilosoPhi34 study

Author

Pungolino, E, D'Adda, M, De Canal, G, Trojani, A, Perego, A, Elena, C, Lunghi, F, Turrini, M, Borin, L, Iurlo, A, Latargia, M, Carraro, M, Spina, F, Artale, S, Anghilieri, M, Molteni, A, Caramella, M, Baruzzo, G, Nichelatti, M, Di Camillo, B, Cairoli, R, Pungolino E, D'adda M, De Canal G, Trojani A, Perego A, Elena C, Lunghi F, Turrini M, Borin L, Iurlo A, Latargia ML, Carraro MC, Spina F, Artale S, Anghilieri M, Molteni A, Caramella M, Baruzzo G, Nichelatti M, Di Camillo B, Cairoli R, Pungolino, E, D'Adda, M, De Canal, G, Trojani, A, Perego, A, Elena, C, Lunghi, F, Turrini, M, Borin, L, Iurlo, A, Latargia, M, Carraro, M, Spina, F, Artale, S, Anghilieri, M, Molteni, A, Caramella, M, Baruzzo, G, Nichelatti, M, Di Camillo, B, Cairoli, R, Pungolino E, D'adda M, De Canal G, Trojani A, Perego A, Elena C, Lunghi F, Turrini M, Borin L, Iurlo A, Latargia ML, Carraro MC, Spina F, Artale S, Anghilieri M, Molteni A, Caramella M, Baruzzo G, Nichelatti M, Di Camillo B, and Cairoli R

Abstract

Chronic Myeloid Leukemia is a clonal disorder characterized by the presence of the Ph-chromosome and the BCR-ABL tyrosine-kinase (TK). Target-therapy with Imatinib has greatly improved its outcome. Deeper and faster responses are reported with the second-generation TKI Nilotinib. Sustained responses may enable TKI discontinuation. However, even in a complete molecular response, some patients experience disease recurrence possibly due to persistence of quiescent leukemic CD34+/lin−Ph+ stem cells (LSCs). Degree and mechanisms of LSCs clearance during TKI treatment are not clearly established. The PhilosoPhi34 study was designed to verify the in-vivo activity and timecourse of first-line Nilotinib therapy on BM CD34+/lin−Ph+ cells clearance. Eighty-seven CP-CML patients were enrolled. BM cells were collected and tested for Ph+ residual cells, at diagnosis, 3, 6 and 12 months of treatment. FISH analysis of unstimulated CD34+/lin− cells in CCyR patients were positive in 8/65 (12.3%), 5/71 (7%), 0/69 (0%) evaluable tests, respectively. Per-Protocol analysis response rates were as follows: CCyR 95% at 12 months, MR4.5 31% and 46% at 12 and 36 months, respectively. An exploratory Gene Expression Profiling (GEP) study of CD34+/lin− cells was performed on 30 patients at diagnosis and after, on 79 patients at diagnosis vs 12 months of nilotinib treatment vs 10 healthy subjects. Data demonstrated some genes significantly different expressed: NFKBIA, many cell cycle genes, ABC transporters, JAK-STAT signaling pathway (JAK2). In addition, a correlation between different expression of some genes (JAK2, OLFM4, ICAM1, NFKBIA) among patients at diagnosis and their achievement of an early and deeper MR was observed.

Published
2021

25. PER2 C111G polymorphism, cognitive reserve and cognition in subjective cognitive decline and mild cognitive impairment: a 10‐year follow‐up study

Author

Bessi, V., primary, Giacomucci, G., additional, Mazzeo, S., additional, Bagnoli, S., additional, Padiglioni, S., additional, Balestrini, J., additional, Tomaiuolo, G., additional, Piaceri, I., additional, Carraro, M., additional, Bracco, L., additional, Sorbi, S., additional, and Nacmias, B., additional

Published
2020
Full Text
View/download PDF

27. Nilotinib induced bone marrow CD34+/lin–Ph+ cells early clearance in newly diagnosed CP-chronic myeloid leukemia

Author

Pungolino, E, Rossi, G, De Canal, G, Trojani, A, D'Adda, M, Perego, A, Orlandi, E, Lunghi, F, Turrini, M, Borin, L, Iurlo, A, Latargia, M, Carraro, M, Spina, F, Lodola, M, Artale, S, Anghilieri, M, Spedini, P, Cantoni, S, Di Camillo, B, Morra, E, Cairoli, R, Pungolino E., Rossi G., De Canal G., Trojani A., D'adda M., Perego A., Orlandi E. M., Lunghi F., Turrini M., Borin L., Iurlo A., Latargia M. L., Carraro M. C., Spina F., Lodola M., Artale S., Anghilieri M., Spedini P., Cantoni S., Di Camillo B., Morra E., Cairoli R., Pungolino, E, Rossi, G, De Canal, G, Trojani, A, D'Adda, M, Perego, A, Orlandi, E, Lunghi, F, Turrini, M, Borin, L, Iurlo, A, Latargia, M, Carraro, M, Spina, F, Lodola, M, Artale, S, Anghilieri, M, Spedini, P, Cantoni, S, Di Camillo, B, Morra, E, Cairoli, R, Pungolino E., Rossi G., De Canal G., Trojani A., D'adda M., Perego A., Orlandi E. M., Lunghi F., Turrini M., Borin L., Iurlo A., Latargia M. L., Carraro M. C., Spina F., Lodola M., Artale S., Anghilieri M., Spedini P., Cantoni S., Di Camillo B., Morra E., and Cairoli R.

Published
2018

28. Combining Imatinib-Following-Nilotinib Treatment in First Line Therapy for Chronic Phase Chronic Myeloid Leukemia. Update from the PhilosoPhi34 Study at 24 Months of Follow-up

Author

Pioltelli, M, Pungolino, E, D'Adda, M, Elena, C, Borin, L, Perego, A, Malato, S, Spina, F, Artale, S, Carraro, M, Orofino, N, Anghilieri, M, Farina, M, Latargia, M, Iurlo, A, Trojani, A, Turrini, M, Caramella, M, Spedini, P, Rossi, G, Morra, E, Cairoli, R, Pioltelli ML, Pungolino E, D'adda M, Elena C, Borin LM, Perego A, Malato S, Spina F, Artale S, Carraro M, Orofino N, Anghilieri M, Farina M, Latargia ML, Iurlo A, Trojani A, Turrini M, Caramella M, Spedini P, Rossi G, Morra E, Cairoli R, Pioltelli, M, Pungolino, E, D'Adda, M, Elena, C, Borin, L, Perego, A, Malato, S, Spina, F, Artale, S, Carraro, M, Orofino, N, Anghilieri, M, Farina, M, Latargia, M, Iurlo, A, Trojani, A, Turrini, M, Caramella, M, Spedini, P, Rossi, G, Morra, E, Cairoli, R, Pioltelli ML, Pungolino E, D'adda M, Elena C, Borin LM, Perego A, Malato S, Spina F, Artale S, Carraro M, Orofino N, Anghilieri M, Farina M, Latargia ML, Iurlo A, Trojani A, Turrini M, Caramella M, Spedini P, Rossi G, Morra E, and Cairoli R

Published
2018

29. Jak-2 and Nfkbia Gene Expression Play a Strategic Role in Chronic Myeloid Leukemia (CML) Molecular Response during Early Nilotinib Treatment: The PhilosoPhi34 Data

Author

Pungolino, E, D'Adda, M, Trojani, A, Perego, D, Pioltelli, M, Rossi, G, Perego, A, Elena, C, Iurlo, A, Malato, S, Turrini, M, De Canal, G, Borin, L, Lodola, M, Caramella, M, Artale, S, Spina, F, Latargia, M, Anghilieri, M, Spedini, P, Carraro, M, Di Camillo, B, Gramegna, D, Morra, E, Cairoli, R, Pungolino E, D'adda M, Trojani A, Perego D, Pioltelli ML, Rossi G, Perego A, Elena C, Iurlo A, Malato S, Turrini M, De Canal G, Borin L, Lodola M, Caramella M, Artale S, Spina F, Latargia ML, Anghilieri M, Spedini P, Carraro M, Di Camillo B, Gramegna D, Morra E, Cairoli R, Pungolino, E, D'Adda, M, Trojani, A, Perego, D, Pioltelli, M, Rossi, G, Perego, A, Elena, C, Iurlo, A, Malato, S, Turrini, M, De Canal, G, Borin, L, Lodola, M, Caramella, M, Artale, S, Spina, F, Latargia, M, Anghilieri, M, Spedini, P, Carraro, M, Di Camillo, B, Gramegna, D, Morra, E, Cairoli, R, Pungolino E, D'adda M, Trojani A, Perego D, Pioltelli ML, Rossi G, Perego A, Elena C, Iurlo A, Malato S, Turrini M, De Canal G, Borin L, Lodola M, Caramella M, Artale S, Spina F, Latargia ML, Anghilieri M, Spedini P, Carraro M, Di Camillo B, Gramegna D, Morra E, and Cairoli R

Published
2018

32. Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223

Author

Steingo, B. Al Malik, Y. Bass, A.D. Berkovich, R. Carraro, M. Fernández, Ó. Ionete, C. Massacesi, L. Meuth, S.G. Mitsikostas, D.D. Pardo, G. Simm, R.F. Traboulsee, A. Choudhry, Z. Daizadeh, N. Compston, D.A.S. the CAMMS223, CAMMS03409, TOPAZ Investigators

Abstract

Background: In the phase 2 CAMMS223 trial (NCT00050778), alemtuzumab significantly improved clinical and MRI outcomes versus subcutaneous interferon beta-1a over 3 years in treatment-naive patients with relapsing–remitting MS. Here, we assess efficacy and safety of alemtuzumab over 12 years in CAMMS223 patients who enrolled in the CAMMS03409 extension (NCT00930553), with available follow-up through the subsequent TOPAZ extension (NCT02255656). Methods: In CAMMS223, patients received 2 alemtuzumab courses (12 mg/day; baseline: 5 days; 12 months later: 3 days); 22% received a third course. In the open-label, nonrandomized extensions, patients could receive as-needed additional alemtuzumab or other disease-modifying therapies. Results: Of 108 alemtuzumab-treated patients in CAMMS223, 60 entered the CAMMS03409 extension; 33% received a total of 2 alemtuzumab courses, and 73% received no more than 3 courses through Year 12. Over 12 years, annualized relapse rate was 0.09, 71% of patients had stable or improved Expanded Disability Status Scale scores, and 69% were free of 6-month confirmed disability worsening. In Year 12, 73% of patients were free of MRI disease activity. Cumulatively throughout the extensions (Years 7–12), 34% of patients had no evidence of disease activity. Adverse event (AE) incidence declined through Year 12. Infusion-associated reactions peaked at first course and declined thereafter. Cumulative thyroid AE incidence was 50%; one immune thrombocytopenia event occurred, and there were no autoimmune nephropathy cases. Conclusions: Alemtuzumab efficacy was maintained over 12 years in CAMMS223 patients, with 73% receiving no more than three courses. The safety profile in this cohort was consistent with other alemtuzumab clinical trials. © 2020, The Author(s).

Published
2020

33. Método de Folin Ciocalteau adaptado para quantificar polifenóis em extratos de erva-mate

Author

LAZZAROTTO, S. R. da S., SCHERRUTH, M. S. de F., CALIXTO, P. S., CARRARO, M. de M., SILVEIRA, A. C. da, LAZZAROTTO, M., SIMONE ROSA DA SILVEIRA LAZZAROTTO, Doutoranda na UEPG, MARIELLY STASYSZEN DE FREITAS SCHERRUTH, FAPAR, PATRICIA STHEFANI CALIXTO, Mestranda na UFPR, MATHEUS DE MELO CARRARO, Graduanda da UEPG, ANA CLAUDIA DA SILVEIRA, Estagiária de pós-graduação na Embrapa Florestas, and MARCELO LAZZAROTTO, CNPF.

Subjects
Erva mate, Polifenois, Planejamento experimental, Method adaptation, Experimental planning, Polyphenols, Cinética de reação, Ilex Paraguariensis, Reaction kinetics, Adaptação de metodologia
Abstract

A folha de erva-mate é consumida tradicionalmente e conhecida pela alta concentração de polifenóis. O método espectrofotométrico comumente usado para determinar o Teor de Polifenóis Totais (CFT) é o Folin-Ciocalteu. O objetivo desse trabalho foi adaptar o método de Folin-Ciocalteau para determinar o CTF em extrato de erva-mate visando a redução do tempo de reação, proporcionando eficiência e economia. Para tanto, a cinética da reação envolvida na análise do extrato de erva-mate foi estudada, sendo observada uma mudança de inclinação da curva cinética em 30 minutos de reação. Para avaliar a adequação do tempo de reação da análise em 30 minutos, a curva padrão foi obtida por três analistas diferentes e os resultados comparados à análise utilizando tempo de reação de 2 horas, conforme método Folin-Ciocalteu. Os resultados foram expressos em equivalente de ácido gálico (EAG). Os resultados de absorbância variaram de 0,004 ± 0,004 (0 mg EAG L-1)a 1,187 ± 0,100 (1000 mg EAG L-1) para a reação de 2 horas. Na reação de 30 minutos estes valores variaram de 0,005 ± 0,004 (0 mg EAG L-1) a 1,197 ± 0,022 (1000 mg EAG L-1). Estes métodos foram utilizados para quantificar o CFT em folhas de erva-mate e osresultados foram de 58,33 ± 3,90 mg EAG g-1(método tradicional) e de 57,77 ± 2,70 mg EAG g-1(método adaptado). Estes resultados demonstram a reprodutibilidade no método adaptado, mostrando a sua utilidade para obter maior eficiência e economia na análise. Made available in DSpace on 2021-04-23T12:34:14Z (GMT). No. of bitstreams: 1 Marcelo-Lazzarotto-Metodo-de-Folin.pdf: 534522 bytes, checksum: 8c266ba044c4d5166c536936dac6665a (MD5) Previous issue date: 2020

Published
2020

36. Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study

Author

Gemelli, M, Elli, E, Elena, C, Iurlo, A, Intermesoli, T, Maffioli, M, Pungolino, E, Carraro, M, D'Adda, M, Lunghi, F, Anghileri, M, Polverelli, N, Rossi, M, Bacciocchi, M, Bono, E, Bucelli, C, Passamonti, F, Antolini, L, Passerini, C, Gemelli, Maria, Elli, Elena Maria, Elena, Chiara, Iurlo, Alessandra, Intermesoli, Tamara, Maffioli, Margherita, Pungolino, Ester, Carraro, Maria Cristina, D'Adda, Mariella, Lunghi, Francesca, Anghileri, Michela, Polverelli, Nicola, Rossi, Marianna, Bacciocchi, Mattia, Bono, Elisa, Bucelli, Cristina, Passamonti, Francesco, Antolini, Laura, Passerini, Carlo Gambacorti, Gemelli, M, Elli, E, Elena, C, Iurlo, A, Intermesoli, T, Maffioli, M, Pungolino, E, Carraro, M, D'Adda, M, Lunghi, F, Anghileri, M, Polverelli, N, Rossi, M, Bacciocchi, M, Bono, E, Bucelli, C, Passamonti, F, Antolini, L, Passerini, C, Gemelli, Maria, Elli, Elena Maria, Elena, Chiara, Iurlo, Alessandra, Intermesoli, Tamara, Maffioli, Margherita, Pungolino, Ester, Carraro, Maria Cristina, D'Adda, Mariella, Lunghi, Francesca, Anghileri, Michela, Polverelli, Nicola, Rossi, Marianna, Bacciocchi, Mattia, Bono, Elisa, Bucelli, Cristina, Passamonti, Francesco, Antolini, Laura, and Passerini, Carlo Gambacorti

Abstract

Background Generic formulations of imatinib mesylate have been introduced in Western Europe since 2017 to treat patients with chronic myeloid leukemia (CML). However, results on the safety and efficacy of generic formulations are contrasting. The aim of this study was to investigate the safety and efficacy of generic imatinib in CML patients treated in 12 Italian institutes. Methods This is an observational, retro-prospective analysis of patients with CML for whom the treatment was switched from brand to generic imatinib. We analyzed and compared the variation in quantitative PCR values before and after the switch, and the proportion of patients who maintained molecular response after changing from brand to generic imatinib. Adverse events (AEs) were also evaluated. Results Two hundred patients were enrolled. The median PCR value after the switch was reduced by 0.25 compared to the values before the switch. A significant difference was found between median PCR values before and after the switch in favor of generic imatinib (P = 0.003). Molecular responses remained stable in 69.0%, improved in 25.5%, and worsened in 5.5% of patients. AEs were similar in the pre- and post-switch periods; however, a significant difference was found in favor of generic imatinib for muscular cramps (P < 0.0001), periorbital edema (P=0.0028), edema of the limbs (P <0.0001), fatigue (P =0.0482), and diarrhea (P=0.0027). Conclusion Our data indicate that generic imatinib does not have deleterious effects on CML control and present an acceptable safety profile, similar or better than brand imatinib.

Published
2020

38. Lack of apparent association between lymphocyte pharmacodynamics and clinical or MRI disease activity in alemtuzumab-treated relapsing-remitting Multiple Sclerosis patients through 6 years: CARE-MS extension

Author

VAN WIJMEERSCH, Bart, Carraro, M., Comi, G., Izquierdo, G., Kim, H. J., Sharrack, B., Tornatore, C., Daizadeh, N., Melanson, M., Jacobs, Alessia, Wiendl, H., VAN WIJMEERSCH, Bart, Carraro, M., Comi, G., Izquierdo, G., Kim, H. J., Sharrack, B., Tornatore, C., Daizadeh, N., Melanson, M., Jacobs, Alessia, and Wiendl, H.

Subjects
parasitic diseases, virus diseases, equipment and supplies
Abstract

Sanofi; Bayer HealthCare Pharmaceuticals

Published
2018

40. As-built Design Report of SPIDER Control Rooms (PBS component 53.SC.CC)

Author

Carraro M., Migliorato L., and Moressa M.

Subjects
Neutral Beam Test Facility, ComputingMethodologies_DOCUMENTANDTEXTPROCESSING, NBTF, SPIDER Central CODAS, SPIDER Control Interlock Safety, F4E RFX, SPIDER
Abstract

This document reports the as-built design of the SPIDER Control rooms.

Published
2019

41. MANUFACTURING DESIGN OF SPIDER SAFETY SYSTEM - VIDEO SURVEILLANCE CAMERA SYSTEM

Author

Grando L., Barbato P., Carraro M., and Baseggio L.

Subjects
NBTF Control Interlock and Safety, neutral beam test facility, NBTF, SPIDER
Abstract

This document is intended as the Manufacturing Design required in Task Order #03 of F4E-OFC-280 Framework Contract for the part related to the Surveillance Camera System (OPTION #03) to be installed in the NBTF buildings.

Published
2019

42. Operation and Maintenance Manuals of the SPIDER Control Rooms

Author

Carraro M., Migliorato L., and Zampiva E.

Subjects
Neutral Beam Test Facility, ComputingMethodologies_DOCUMENTANDTEXTPROCESSING, NBTF, SPIDER Central CODAS, SPIDER Control Interlock and Safety, F4E RFX, SPIDER
Abstract

This document contains the operation and maintenance manuals of the SPIDER Control room.

Published
2019

43. Vacuum High Voltage Holding: DC Experiments and modelling

Author

Pilan N., Barbato P., Baseggio L., Battistella M., Bernardi M., Carraro M., Cavazzana R., Cervaro V., Cinetto P., De Lorenzi A., Fincato M., Fontana C., Friso D., Gobbo G., Grosso B., Laterza L., Lotto L., Manduchi G., Maniero M., Muraro A., Martines E., Mc Cormack O., Migliorato L., Moretti M., Nobili P., Patton T., Pesavento G., Pino F., Polato S., Rigoni A., Rigamonti D., Rizzieri R., Romanato L., Rossetto F., Spada E., Spagnolo S., Taliercio C., Tiso A., vignando M., and Zuin M.

Subjects
F4E-RFX, Vacuum High Voltage Holding, Neutral Beam Test Facility, HVPTF, High Voltage Padova Test Facility, NBTF
Abstract

This report describes the activities carried out within the subtask T5.7 of the Work Programme WP2019 at the High Voltage Padova Test Facility HVPTF and on the new High Voltage Short Gap Test Facility HVSGTF. The activities mainly consisted in: 1) Test of two electrodes with double-polarity configurations (Common Mode Voltage tests). 2) Test of electropolished electrodes 3) Tests with cathode covered by a thick alumina cap 4) Removal of dust deposited inside the vacuum vessel before starting the vacuum system: 5) Tests with specific shaped electrodes designed to understand the effect of the mutual exchange of charged particles between electrodes are still in progress 6) Tests of Non Evaporable Getter (NEG) pumps at high voltage in high vacuum are still in progress 7) Ordinary Maintenance of the vacuum pump system 8) Tests in HVSGTF to measure the Fowler-Nordheim emission current from stainless steel electrodes. The activities mentioned in points #5 and #6 are still in progress and will be completed next year. Concerning the other experiments, the main outcomes can be reported as follows: 1) CMV tests showed that the main microdischarge activity of the electrodes appears to be related to phenomena involving only a single power supply unit and the vacuum chamber, rather than the two electrodes under test 2) Test of electropolished electrodes, tests with cathode covered by a thick alumina cap and Removal of dust deposited inside the vacuum vessel did not indicate significant improvements of voltage holding 3) The measurement of the Fowler-Nordheim emission current from stainless steel electrodes showed a behaviour much more complex than expected and their analysis is in progress.

Published
2019

44. IDENTIFICATION OF MIRNA AND TARGET GENES IN THE TRANSCRIPTOME ANALYSIS OF CD34+/LIN- CELLS OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AFTER 12 MONTHS OF NILOTINIB THERAPY

Author

Trojani, A., Pungolino, E., Dal Molin, A., Luca Emanuele Bossi, Rossi, G., D Adda, M., Perego, A., Elena, C., Turrini, M., Borin, L., Bucelli, C., Malato, S., Carraro, M. C., Spina, F., Latargia, M. L., Artale, S., Spedini, P., Anghilieri, M., Di Camillo, B., Baruzzo, G., Canal, G., Iurlo, A., Morra, E., and Cairoli, R.

Published
2019

45. WP2019 MITICA SAFETY ACTIVITY REPORT

Author

Battistella M., Grando L., Breda M., Moressa M., Barbato P., Carraro M., Baseggio L., Cinetto P., Caon M., Zucchetti S., Ghiraldelli R., Rizzieri R., and Vignando M.

Subjects
MITICA, Neutral Beam Test Facility, NBTF, F4E-RFX-PMS
Abstract

The MITICA Central Safety System (MITICA CSS) implements a set of important protection functions related to personnel health and safety, both during and outside the operation of the MITICA test bed, providing continuous monitoring of potentially dangerous events, automated protection actions, and logging of events and data relevant for safety of people. The Technical Specification for the call for tender of the supply of the MITICA CSS was drafted in 2017 (ref. RFX_MITICA_TS_041), but some important details were still to be defined, also depending on the status of the procurement of plant systems interfacing with MITICA CSS and according to the experience acquired with SPIDER CSS installation. This document is intended to be the report of the main activities related to MITICA safety carried out in 2019, in order to better define the aspects needed to pass from the MITICA CSS "Draft" to the "Detailed" Techinical Specification.

Published
2019

46. MANUFACTURING DESIGNOF SPIDER SAFETY SYSTEM - RADIOPROTECTION INSTRUMENTATION

Author

Battistella M., Carraro M., and Grando L.

Subjects
SPIDER Control & Data Acquisition Interlock and Safety, F4E-RFX, Neutral Beam Test Facility, NBTF, SPIDER CODAS, F4E-OFC, SPIDER
Abstract

This document is intended as the Manufacturing Design required in Task Order #03of F4E-OFC-280 Framework Contract for the part related to radioprotection instrumentation(OPTION #02)installed in NBTF buildings.

Published
2019

47. P6547The energy cost of His bundle pacing can be curtailed

Author

Zanon, F, primary, Marcantoni, L, additional, Pastore, G, additional, Baracca, E, additional, Picariello, C, additional, Lanza, D, additional, Maddalozzo, A, additional, Giatti, S, additional, Carraro, M, additional, Roncon, L, additional, Barbetta, A, additional, and Di Gregorio, F, additional

Published
2019
Full Text
View/download PDF

49. PH plus STEM CELLS (SCS) IN CHRONIC MYELOID LEUKEMIA (CML): TO ERADICATE OR NOT TO ERADICATE, THIS IS THE QUESTION

Author

Pungolino, E, D'Adda, M, Trojani, A, Perego, A, Elena, C, Iurlo, A, Malato, S, Turrini, M, De Canal, G, Borin, L, Bossi, L, Caramella, M, Artale, S, Spina, F, Latargia, M, Anghilieri, M, Spedini, P, Carraro, M, Di Camillo, B, Gramegna, D, Pioltelli, M, Rossi, G, Morra, E, Cairoli, R, Pungolino E, D'adda M, Trojani A, Perego A, Elena C, Iurlo A, Malato S, Turrini M, De Canal G, Borin L, Bossi LE, Caramella M, Artale S, Spina F, Latargia ML, Anghilieri M, Spedini P, Carraro MC, Di Camillo B, Gramegna D, Pioltelli ML, Rossi G, Morra E, Cairoli R, Pungolino, E, D'Adda, M, Trojani, A, Perego, A, Elena, C, Iurlo, A, Malato, S, Turrini, M, De Canal, G, Borin, L, Bossi, L, Caramella, M, Artale, S, Spina, F, Latargia, M, Anghilieri, M, Spedini, P, Carraro, M, Di Camillo, B, Gramegna, D, Pioltelli, M, Rossi, G, Morra, E, Cairoli, R, Pungolino E, D'adda M, Trojani A, Perego A, Elena C, Iurlo A, Malato S, Turrini M, De Canal G, Borin L, Bossi LE, Caramella M, Artale S, Spina F, Latargia ML, Anghilieri M, Spedini P, Carraro MC, Di Camillo B, Gramegna D, Pioltelli ML, Rossi G, Morra E, and Cairoli R

Published
2019

50. IDENTIFICAZIONE DI MIRNA E GENI TARGET NELL’ANALISI TRASCRITTOMICA DELLE CELLULE CD34+/LIN- DI PAZIENTI CON LEUCEMIA MIELOIDE CRONICA IN FASE CRONICA DOPO 12 MESI DI TERAPIA CON NILOTINIB

Author

Trojani, A, Pungolino, E, Dal Molin, A, Bossi, L, Rossi, G, D'Adda, M, Perego, A, Elena, C, Turrini, M, Borin, L, Bucelli, C, Malato, S, Carraro, M, Spina, F, Latargia, M, Artale, S, Spedini, P, Anghilieri, M, Di Camillo, B, Baruzzo, G, De Canal, G, Iurlo, A, Morra, E, Cairoli, R, Trojani A, Pungolino E, Dal Molin A, Bossi LE, Rossi G, D'Adda M, Perego A, Elena C, Turrini M, Borin L, Bucelli C, Malato S, Carraro MC, Spina F, Latargia ML, Artale S, Spedini P, Anghilieri M, Di Camillo B, Baruzzo G, De Canal G, Iurlo A, Morra E, Cairoli R, Trojani, A, Pungolino, E, Dal Molin, A, Bossi, L, Rossi, G, D'Adda, M, Perego, A, Elena, C, Turrini, M, Borin, L, Bucelli, C, Malato, S, Carraro, M, Spina, F, Latargia, M, Artale, S, Spedini, P, Anghilieri, M, Di Camillo, B, Baruzzo, G, De Canal, G, Iurlo, A, Morra, E, Cairoli, R, Trojani A, Pungolino E, Dal Molin A, Bossi LE, Rossi G, D'Adda M, Perego A, Elena C, Turrini M, Borin L, Bucelli C, Malato S, Carraro MC, Spina F, Latargia ML, Artale S, Spedini P, Anghilieri M, Di Camillo B, Baruzzo G, De Canal G, Iurlo A, Morra E, and Cairoli R

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results